Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state

Cancer Research

Volumn 72, Issue 16, 2012, Pages 3987-3996

  Teng, Michele W L ^a,b   Vesely, Matthew D ^c   Duret, Helene ^a   McLaughlin, Nicole ^a   Towne, Jennifer E ^d   Schreiber, Robert D ^c   Smyth, Mark J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; ALPHA INTERFERON; ANTIBODY; BETA INTERFERON; CD40 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 23P19 ANTIBODY; INTERLEUKIN 23P40; INTERLEUKIN 4; PROTEIN P53; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DORMANCY; EQUILIBRIUM PHASE; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; OCCULT CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; FIBROSARCOMA; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-23; LYMPHOCYTE ACTIVATION; MALE; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES;

EID: 84865116628     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1337     Document Type: Article

References (33)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
3. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400-4.
4. Weinhold KJ, Miller DA, Wheelock EF. The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination. J Exp Med 1979;149:745-57. (Pubitemid 9137686)
5. Weinhold KJ, Goldstein LT, Wheelock EF. The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. J Exp Med 1979;149:732-44. (Pubitemid 9137685)
6. Matsuzawa A, Takeda Y, Narita M, Ozawa H. Survival of leukemic cells in a dormant state following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (DL811). Int J Cancer 1991;49:303-9.
7. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7. (Pubitemid 350231320)
8. Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T, et al. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med 2007;204:879-91. (Pubitemid 46631616)
9. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010;120:2030-9.
10. Langowski JL, Zhang X,WuL, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-5. (Pubitemid 44264796)
11. Teng MW, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Moller A, et al. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci USA 2010;107:8328-33.
12. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2011;66:742-51.
13. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011;365:1586-96.
14. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994;73:2759-64. (Pubitemid 24166263)
15. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62. (Pubitemid 32173312)
16. Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hammerling GJ, Schwendener R, et al. CD11c+dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol 2010;185:532-41.
17. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192:755-60.
18. Swann JB, Uldrich AP, van Dommelen S, Sharkey J, Murray WK, Godfrey DI, et al. Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 2009;113:6382-5.
19. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-61. (Pubitemid 28293291)
20. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-9. (Pubitemid 34461260)
21. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9. (Pubitemid 41716746)
22. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008;105:652-6. (Pubitemid 351171763)
23. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008;13:507-18. (Pubitemid 351763899)
24. Houghton J, Li H, Fan X, Liu Y, Liu JH, Rao VP, et al. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev 2010;19:1153-66.
25. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114-23.
26. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-81.
27. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective anti-angiogenic therapy approach. Br J Cancer 2006;95:272-81. (Pubitemid 44187587)
28. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. (Pubitemid 351671883)
29. Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011;71:1733-53.
30. Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2011;132:304-14.
31. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41.
32. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010;33:279-88.
33. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3. (Pubitemid 44871953)